Oppenheimer & Co. Inc. Takes Position in Addus HomeCare Co. (NASDAQ:ADUS)

Oppenheimer & Co. Inc. purchased a new position in shares of Addus HomeCare Co. (NASDAQ:ADUSGet Rating) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,255 shares of the company’s stock, valued at approximately $211,000.

Other large investors have also added to or reduced their stakes in the company. Northern Trust Corp grew its position in Addus HomeCare by 10.4% during the fourth quarter. Northern Trust Corp now owns 285,427 shares of the company’s stock worth $26,690,000 after buying an additional 26,787 shares in the last quarter. Virginia Retirement Systems ET AL acquired a new stake in shares of Addus HomeCare in the 1st quarter valued at $252,000. Chatham Capital Group Inc. boosted its holdings in shares of Addus HomeCare by 75.4% in the 1st quarter. Chatham Capital Group Inc. now owns 19,443 shares of the company’s stock valued at $1,814,000 after purchasing an additional 8,357 shares in the last quarter. Shell Asset Management Co. boosted its holdings in shares of Addus HomeCare by 110.1% in the 1st quarter. Shell Asset Management Co. now owns 2,725 shares of the company’s stock valued at $254,000 after purchasing an additional 1,428 shares in the last quarter. Finally, MQS Management LLC acquired a new stake in shares of Addus HomeCare in the 1st quarter valued at $276,000. Institutional investors and hedge funds own 95.03% of the company’s stock.

Insider Buying and Selling

In related news, EVP David W. Tucker sold 2,080 shares of the firm’s stock in a transaction on Friday, July 15th. The stock was sold at an average price of $90.00, for a total transaction of $187,200.00. Following the completion of the transaction, the executive vice president now directly owns 8,468 shares of the company’s stock, valued at approximately $762,120. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Sean Gaffney sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $95.00, for a total transaction of $950,000.00. Following the completion of the transaction, the executive vice president now directly owns 14,413 shares of the company’s stock, valued at approximately $1,369,235. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP David W. Tucker sold 2,080 shares of the firm’s stock in a transaction on Friday, July 15th. The stock was sold at an average price of $90.00, for a total value of $187,200.00. Following the transaction, the executive vice president now directly owns 8,468 shares of the company’s stock, valued at $762,120. The disclosure for this sale can be found here. Insiders sold a total of 29,295 shares of company stock valued at $2,752,735 in the last three months. Insiders own 4.50% of the company’s stock.

Addus HomeCare Stock Up 4.2 %

Shares of ADUS opened at $91.64 on Thursday. Addus HomeCare Co. has a 52 week low of $68.57 and a 52 week high of $108.11. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 33.20, a PEG ratio of 2.35 and a beta of 0.86. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a fifty day moving average of $91.22 and a 200-day moving average of $85.75.

Addus HomeCare (NASDAQ:ADUSGet Rating) last announced its quarterly earnings results on Monday, August 1st. The company reported $0.91 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.01). The firm had revenue of $236.94 million during the quarter, compared to the consensus estimate of $238.40 million. Addus HomeCare had a net margin of 4.90% and a return on equity of 8.63%. The firm’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.78 earnings per share. As a group, sell-side analysts anticipate that Addus HomeCare Co. will post 3.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Oppenheimer reduced their target price on Addus HomeCare from $135.00 to $130.00 and set an “outperform” rating on the stock in a report on Wednesday, August 3rd. StockNews.com downgraded Addus HomeCare from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 20th. Stifel Nicolaus assumed coverage on Addus HomeCare in a report on Tuesday, June 28th. They issued a “buy” rating and a $101.00 target price on the stock. Stephens reduced their target price on Addus HomeCare from $110.00 to $101.00 and set an “overweight” rating on the stock in a report on Tuesday, June 21st. Finally, Royal Bank of Canada dropped their price target on Addus HomeCare from $111.00 to $110.00 and set an “outperform” rating for the company in a research note on Wednesday, August 3rd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $110.40.

Addus HomeCare Profile

(Get Rating)

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health.

Featured Stories

Want to see what other hedge funds are holding ADUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Addus HomeCare Co. (NASDAQ:ADUSGet Rating).

Institutional Ownership by Quarter for Addus HomeCare (NASDAQ:ADUS)

Receive News & Ratings for Addus HomeCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus HomeCare and related companies with MarketBeat.com's FREE daily email newsletter.